Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 265-270

  Zucali, P A ^a   Perrino, M ^a   Lorenzi, E ^a   Ceresoli, G L ^b   De Vincenzo, F ^a   Simonelli, M ^a   Gianoncelli, L ^a   De Sanctis, R ^a   Giordano, L ^a   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

Author keywords

Activity and toxicity; Chemotherapy; Malignant pleural mesothelioma; Pemetrexed pretreated patients; Second or further line; Vinorelbine

Indexed keywords

NAVELBINE; PEMETREXED; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PLEURAL NEOPLASMS; PROCEDURES; SALVAGE THERAPY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; VINBLASTINE;

EID: 84901932964     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.011     Document Type: Article

References (35)

1. Zucali P.A., De Vincenzo F., Simonelli M., Santoro A. Future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther 2009, 9:453-467.
2. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
3. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003, 21:1556-1561.
4. Ceresoli G.L., Zucali P.A., Favaretto A.G., Grossi F., Bidoli P., Del Conte G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006, 24:1443-1448.
5. Castagneto B., Botta M., Aitini E., Spigno F., Degiovanni D., Alabiso O., et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008, 19:370-373.
6. Santoro A., O'Brien M.E., Stahel R.A., Nackaerts K., Baas P., Karthaus M., et al. Pemetrexed plus cisplatin or pemetrexed plus carbolatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008, 3:756-763.
7. Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16:923-927.
8. Vogelzang N.J. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?. J Clin Oncol 1999, 17:2626-2627.
9. Giaccone G., O'Brien M.E., Byrne M.J., Bard M., Kaukel E., Smit B., et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002, 38:S19-S24.
10. Fizazi K., Doubre H., Le Chevalier T., RiviereF A., Viala J., Daniel C., et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003, 21:349-354.
11. Porta C., Zimatore M., Bonomi L., Imarisio I., Paglino C., Sartore-Bianchi A., et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005, 48:429-434.
12. Janne P.A., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J., Polikoff J.A., et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006, 1:506-512.
13. Sorensen J.B., Sundstrom S., Perrell K., Thielsen A.K. Pemetrexed as second-line treatment in malignant pleural mesothelioma (MPM) after platinum-based first-line treatment. J Thorac Oncol 2007, 2:147-152.
14. Fennell D.A., Steele J.P., Shamash J., Evans M.T., Wells P., Sheaff M.T., et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007, 109:93-99.
15. Jassem J., Ramlau R., Santoro A., Schuette W., Chemaissani A., Hong S., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26:1698-1704.
16. Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112:1555-1561.
17. Gregorc V., Zucali P.A., Santoro A., Ceresoli G.L., Citterio G., De Pas T.M., et al. Phase II Study of asparagine-glycine-arginine-human tumor necrosis factor {alpha}, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010, 28:2604-2611.
18. Ceresoli G.L., Zucali P.A., Gianoncelli L., Lorenzi E., Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010, 36:24-32.
19. Ceresoli G.L., Zucali P.A., De Vincenzo F., Gianoncelli L., Simonelli M., Lorenzi E., et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011, 72:73-77.
20. Bearz A., Talamini R., Rossoni G., Santo A., de Pangher V., Fasola G., et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes 2012, 5:482.
21. Talbot D.C., Margery J., Dabouis G., Dark G., Taylor H., Boussemart H., et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007, 5:4751-4756.
22. Steele J.P., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., Rudd R.M., et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000, 18:3912-3917.
23. Muers M.F., Stephens R.J., Fisher P., Darlison L., Higgs C.M., Lowry E., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371:1685-1694.
24. Maruyama R., Shoji F., Okamoto T., Miyamoto T., Miyake T., Nakamura T., et al. Triplet chemotherapy with cisplatin, gemcitabin and vinorelbina for malignant pleural mesothelioma. Jpn J Clin Oncol 2005, 35:433-438.
25. Fennell D.A., Steele J.P.C., Shamash J., Sheaff M.T., Goonewardene T.I., Nystrom M.L., et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005, 47:277-281.
26. Sorensen J.B., Frank H., Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008, 99:44-50.
27. Stebbing J., Powles T., McPherson K., Shamash J., Wells P., Sheaff M.T., et al. The efficacy and safety of weekly vinorelbina in relepsed malignant pleural mesothelioma. Lung Cancer 2009, 63:94-97.
28. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
29. National Cancer Institute: Common Toxicity Criteria Manual, version 3.0, August 9, 2006. http://ctep.cancer.gov/reporting/ctc.html.
30. Kaplan E.L., Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958, 53:457-481.
31. Schemper M., Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
32. Hazarika M., White R.M., Booth B.P., Wang Y.C., Ham D.Y., Liang C.Y., et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005, 11:982-992.
33. Armato S.G., Oxnard G.R., MacMahon H., Vogelzang N.J., Kindler H.L., Kocherginsky M., et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys 2004, 31:1105-1115.
34. Van Glabbeke M., Verweij J., Judson I., Nielsen O.S., EORTC Soft Tissue and Bone Sarcoma Group Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38:543-549.
35. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., Giaccone G., et al. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J Clin Oncol 1998, 16:145-152.